The FDA has lifted a partial clinical hold that was placed on the phase III CANOVA (M13-494; NCT03539744) trial, which is examining venetoclax in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma that harbors t(11;14), according to AbbVie, the company that co-develops the BCL-2 inhibitor with Roche.
S. Vincent Rajkumar, MD, discusses the rapidly changing landscape for the treatment of multiple myeloma, the future of immunomodulatory drugs, and whether quadruplet regimens will become more frequent.
Despite promising progression-free survival and response data with venetoclax in combination with bortezomib and dexamethasone, an increased number of deaths due to infection in the experimental arm marred overall survival findings in patients with relapsed/refractory multiple myeloma.
The triplet regimen of elotuzumab plus pomalidomide and dexamethasone led to a 46% reduction in the risk of death compared with pomalidomide/dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to updated findings of the phase II ELOQUENT-3 trial.
While the expansion of therapeutic opportunity in multiple myeloma has been incremental in some ways, it’s been continuous and, when seen in aggregate, the impact is considerable.
Yubin Kang, MD, discusses how progress made in frontline therapy has impacted the outlook of multiple myeloma and the remaining work that needs to be done across settings.
Adding isatuximab to pomalidomide and low-dose dexamethasone led to a greater than 40% reduction in the risk of disease progression or death compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.
A subcutaneous flat-dose version of daratumumab demonstrated noninferior efficacy with a reduction in the treatment burden compared with the original intravenous formulation of the anti-CD38 monoclonal antibody for patients with relapsed/refractory multiple myeloma.
Higher income was associated with significantly greater probability of survival for patients with multiple myeloma, according to authors of a study they performed to call attention to the need to address socioeconomic disparities that influence treatment outcomes.
The FDA has granted a priority review designation to a supplemental biologics license application for daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.